Background Recombinant factor VIIa (rFVIIa) is registered for use in haemophilia with inhibitors and other rare bleeding disorders, but has also been used in various other clinical conditions to terminate life-threatening bleeding. Underlying conditions (e.g. coagulopathy) and dosing may affect treatment efficacy. The objective of the present study was to evaluate the impact of increasing doses of rFVIIa on blood loss and coagulation assays in haemodiluted and hypothermic pigs undergoing blunt liver injury. Methods A grade III blunt liver injury was induced in 28 pigs after 70 % haemodilution and cooling to 32.6–33.4°C. Ten minutes after trauma, animals randomly received placebo or 90, 180 or 360 μg/kg rFVIIa. Global coagulation parameters,...
BACKGROUND: In recent years, the hemostatic agent recombinant factor VIIa (rFVIIa) has emerged as a ...
BACKGROUND: In recent years, the hemostatic agent recombinant factor VIIa (rFVIIa) has emerged as a ...
BACKGROUND: The potential clinical benefits of targeted therapy with coagulation factor concentrates...
Background Recombinant factor VIIa (rFVIIa) is registered for use in haemophilia with inhibitors and...
Recombinant factor VIIa (rFVIIa) is registered for use in haemophilia with inhibitors and other rare...
BACKGROUND: Recombinant factor VIIa (rFVIIa) has been used to decrease bleeding in a number of setti...
Background. We considered whether haemorrhage after a liver trauma would be reduced by early adminis...
Background This study describes the current use of recombinant activated factor VII (rFVIIa) for hem...
Recombinant factor Vila (rFVIIa) is registered for treatment of inhibitor-complicated haemophilia, a...
Recombinant human factor VIIa (rFVIIa) is approved by the US Food and Drug Administration for use in...
Orthotopic liver transplantation (OLT) can be associated with excessive blood loss. As a result, the...
Despite increasing use of prothrombin complex concentrate (PCC) to treat hemorrhage-associated coagu...
BACKGROUND: Recombinant factor VIIa (rFVIIa) is a novel haemostatic agent originally developed to tr...
factor VII (rFVIIa) was approved for treatment of hemorrhages in patients with hemophilia who develo...
Besides the conventional laboratory tests, thromboelastography (TEG) is used to monitor hemostasis d...
BACKGROUND: In recent years, the hemostatic agent recombinant factor VIIa (rFVIIa) has emerged as a ...
BACKGROUND: In recent years, the hemostatic agent recombinant factor VIIa (rFVIIa) has emerged as a ...
BACKGROUND: The potential clinical benefits of targeted therapy with coagulation factor concentrates...
Background Recombinant factor VIIa (rFVIIa) is registered for use in haemophilia with inhibitors and...
Recombinant factor VIIa (rFVIIa) is registered for use in haemophilia with inhibitors and other rare...
BACKGROUND: Recombinant factor VIIa (rFVIIa) has been used to decrease bleeding in a number of setti...
Background. We considered whether haemorrhage after a liver trauma would be reduced by early adminis...
Background This study describes the current use of recombinant activated factor VII (rFVIIa) for hem...
Recombinant factor Vila (rFVIIa) is registered for treatment of inhibitor-complicated haemophilia, a...
Recombinant human factor VIIa (rFVIIa) is approved by the US Food and Drug Administration for use in...
Orthotopic liver transplantation (OLT) can be associated with excessive blood loss. As a result, the...
Despite increasing use of prothrombin complex concentrate (PCC) to treat hemorrhage-associated coagu...
BACKGROUND: Recombinant factor VIIa (rFVIIa) is a novel haemostatic agent originally developed to tr...
factor VII (rFVIIa) was approved for treatment of hemorrhages in patients with hemophilia who develo...
Besides the conventional laboratory tests, thromboelastography (TEG) is used to monitor hemostasis d...
BACKGROUND: In recent years, the hemostatic agent recombinant factor VIIa (rFVIIa) has emerged as a ...
BACKGROUND: In recent years, the hemostatic agent recombinant factor VIIa (rFVIIa) has emerged as a ...
BACKGROUND: The potential clinical benefits of targeted therapy with coagulation factor concentrates...